PUM2

Across TCGA pan-cancer cohorts, PUM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PUM2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PUM2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PUM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where PUM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.270	1.000	.021	15	view →
PDAC	DFS	Tertile	II,III,IV	0.348	0.542	.018	13	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.802	.021	11	view →
GBM	OS	Tertile	All	0.588	0.390	.012	10	view →
CCRCC	DFS	Quartile	III,IV	0.732	1.000	.019	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PUM2–HNSC (OS)

Open the HNSC breakdown →